drugset
drugset / Trial / NCT02839941

Iguratimod in Kidney Transplant Recipients

NCT02839941 ↗

Unknown 60 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.

Timeline

Start
2016-08
Primary completion
2019-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule — Oral
Background Mycophenolate Mofetil Small molecule — —
Background Tacrolimus Small molecule — —

Indications

No indication recorded.